SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 21, 2012
SPECTRUM PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Registrants telephone number, including area code: (702) 835-6300
(Former name or former address if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Item 7.01 Regulation FD Disclosure
On November 21, 2012, Spectrum Pharmaceuticals, Inc. (the Company), filed a replacement registration statement on Form S-3 (the New Registration Statement) to cover an aggregate of up to $250,000,000 of securities that were never sold under a previously filed registration statement on Form S-3 (File No. 333-163366) filed on November 25, 2009 that was not used. That Registration Statement is set to expire on January 12, 2013 (the Expiring Registration Statement). The purpose of the New Registration Statement is to just replace the Expiring Registration Statement and effectively extend the Companys benefits of registration for an additional 3 year period. The Expiring Registration Statement will be deemed terminated automatically as of the effective date of the New Registration Statement.
In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01 of this Current Report on Form 8-K is being furnished and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: November 21, 2012